Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist

2026-02-09 16:57:42 ET

Investment Overview

The stock of Durham, North Carolina-based biotech Humacyte, Inc. ( HUMA ) is buoyant today—up ~28% at the time of writing, with a share price of $1.2 and a market cap of $236m—on news that, according to a press release :

the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries.

The FY2026 National Defense Authorization Act ((NDAA)), enacted in December 2025, stated in report language that DoD should “integrate FDA-approved breakthrough vascular repair technologies in traumatic extremity arterial injury repair, providing an off-the-shelf, biologically active vascular conduit when autologous vein harvesting is not feasible.”

In doing so, lawmakers demonstrated that they recognize and understand the need for human-derived bioengineered vessels to save life and limb on the battlefield.

Humacyte is grateful to see Congress express even greater support for this medical innovation by designating appropriated funds to advance the goal of making this groundbreaking technology available to service members.

Read the full article on Seeking Alpha

For further details see: